title: Analysis of differential therapeutic strategies for primary breast lymphoma: two case reports.
abstract: Primary breast lymphoma (PBL) is a rare form of extranodal non-Hodgkin's lymphoma (NHL), whose own specific biological characteristics still need to be fully defined. No significant prognostic factor has been found and the optimal therapeutic strategy is uncertain. However, an intensified systemic therapy has been advocated to prevent relapse, even in patients who show a complete response to local treatment. We report two cases of primary diffuse large B-cell breast lymphoma, review the literature about this topic, and discuss treatment options. We conclude that differential therapeutic strategies based on the risk of relapse associated with the International Prognostic Index (IPI) are a reasonable way to approach PBL, and can avoid undue toxicity deriving from treatment.
authors.affiliation: Department of Medical Sciences, Regina Apostolorum Hospital, Via S. Francesco, Albano Laziale 5000041, Italy. roberto.stasi@uniroma2.it
authors.forename: Roberto
authors.initials: R
authors.lastname: Stasi
authors.forename: Maria Laura
authors.initials: ML
authors.lastname: Evangelista
authors.forename: Maurizio
authors.initials: M
authors.lastname: Brunetti
authors.forename: Stefano
authors.initials: S
authors.lastname: Bussa
authors.forename: Raffaele
authors.initials: R
authors.lastname: Maritati
authors.forename: Luca
authors.initials: L
authors.lastname: Turrini
authors.forename: Silvia
authors.initials: S
authors.lastname: Taccogna
authors.forename: Anna
authors.initials: A
authors.lastname: Crescenzi
authors.forename: Francesco
authors.initials: F
authors.lastname: Angelini
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D001940:Breast / Q000737:chemistry / Q000473:pathology / Q000503:physiopathology; D001943:Breast Neoplasms / Q000097:blood / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007278:Injections, Spinal; D007770:L-Lactate Dehydrogenase / Q000097:blood; D002955:Leucovorin / Q000627:therapeutic use; D017493:Leukocyte Common Antigens; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D015412:Mastectomy, Segmental; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000964:Antimetabolites, Antineoplastic; D001761:Bleomycin; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007770:L-Lactate Dehydrogenase; D017493:Leukocyte Common Antigens; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate